IBI3005 combination therapy for advanced lung cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new combination drug treatment (IBI3005) for people with advanced or spreading lung cancer that cannot be removed by surgery. The trial aims to find the right dose and see if this treatment can help slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with advanced or spreading non-small cell lung cancer (NSCLC) that cannot be surgically removed
- Expected to live at least 12 weeks
- Good overall health and heart function (left ventricular ejection fraction ≥50%)
- Normal blood cell counts and organ function
- Able to attend study visits and follow all study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests an experimental drug called IBI3005 for people whose solid tumors (cancers that form lumps) have continued to grow despite treatment with a specific targeted therapy (EGFR TKI). The goal is to see if IBI3005 can help when other treatments have stopped working.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.